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Abstract
Objective The aim of this study was to determine the
efficacy of sustained-release fampridine (4-aminopyridine)
in veterans with multiple sclerosis (MS) with limited
ambulatory ability, and its impact on motor function in an
outpatient setting.
Design Retrospective.
Setting Tertiary referral center [Veterans Affairs (VA)
Medical Center].
Participants Veterans; 20 MS patients were prescribed
dalfampridine (10 mg twice daily) due to their difficulty
with walking based on patient and caregiver report and
clinician impression of change in the ability to ambulate
based on prior 10-meter (10M) and 2-minute walk tests
(2MWTs).
Intervention Not applicable.
Main Outcome Measures The primary outcome measures
were mean changes in walking speed (10M walk test),
walking distance (2MWT), and Total Functional
Independence Measure (TFIM). Improvement of[20 % in
walking speed was indicated as a clinically meaningful
change.
Results Treatment with dalfampridine resulted in signif-
icant improvement in walking speed and endurance
(p \ 0.05). Walking speed increased by 33 % and walking
endurance by 31 %, representing clinically meaningful
improvement. This change was not influenced by change in
muscle tone. This improvement in mobility was associated
with a clinically significant change in motor function.
Adverse effects, including insomnia, dizziness, and head-
ache, were experienced by five patients who discontinued
the medication after a minimum of 4 weeks.
Conclusion Treatment with dalfampridine resulted in
clinically relevant improvements in walking speed and
endurance in MS patients with limited ambulation and
helped improve their motor function.
1 Introduction
Gait disturbance is reported by many patients with multiple
sclerosis (MS) as a major primary symptom [1] and occurs
in 50 % of cases [2]. It presents early in the course of the
disease [3] and is perceived as a major health issue by
patients with MS [4]. It is a limiting factor with progression
of the disease [1]. This gait disturbance is caused by
muscle weakness and spasticity from pyramidal tract
lesions, ataxia from cerebellar lesions, sensory disturbance
due to dorsal column lesions, and vestibular and visual
dysfunction, or a combination of these symptoms [5]. It
impacts upon their activities of daily living and emotional
state, and thus decreases their quality of life and health
state [6]. Recommended treatment options specific to gait
disturbance have mainly been physical therapy measures
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such as exercises for strengthening affected muscles,
reducing spasticity, use of ankle–foot braces, and rolling
walkers. None of the current immunomodulatory therapies
have any effect on improving gait disturbance. Thus, gait
disturbance is an important outcome measure in the treat-
ment and rehabilitation of patients with MS.
Fampridine (4-aminopyridine) is a voltage-dependent
potassium channel-blocker [7, 8] found to restore action
potential conduction in poorly myelinated central nerve
fibers [9] and also affects synaptic transmission and neu-
ronal excitability [10]. Several clinical trials have shown
fampridine use has been associated with clinical improve-
ment in MS patients [11–14]. The adverse effects of fam-
pridine are confusion, seizure disorder, and balance
disorders [15, 16]. These adverse effects are directly rela-
ted to its dosing and plasma concentration [17, 18].
Recently, two phase III studies showed sustained-release
oral fampridine (dalfampridine), a long-acting form with
similar physiological action, improved walking ability in
35–43 % of MS patients with ambulatory difficulty com-
pared with 8–9 % for placebo. In the treated group, the
improvement in walking speed was 25 % during the
treatment period [19, 20]. Dalfampridine is nowadays
considered the standard of care for MS patients with
ambulatory difficulty.
The objective of the present study was to replicate these
findings in veterans with MS in an outpatient setting (real-
world environment) and its impacts on their motor function.
2 Methods
2.1 Study Population and Procedures
This study was approved by the Institutional Review Board
of the University of Oklahoma and the Veterans Affairs
Medical Center Research and Development Committee.
Retrospective chart review was conducted for MS patients
(n = 20) regularly followed in an outpatient MS clinic who
were prescribed dalfampridine (10 mg twice daily). The
inclusion criteria were difficulty with walking based on
(i) the patient and caregiver report; and (ii) clinician’s
impression of change in ambulation based on prior
10-meter (10M) and 2-minute walk tests (2MWT). Exclu-
sion criteria included (i) renal impairment (creatinine
clearance \50 mL/min); (ii) prior or current history of
seizure disorder; and (iii) presence of disease instability as
evidenced by recent MS relapse and/or change in immu-
nomodulatory therapy. Patients were non-Hispanic White
(85 %) males (100 %), aged 33–72 years (55.3 ± 10.8;
mean ± SD) (see Table 1).
Data collected from the charts of the 20 patients inclu-
ded demographic information, MS characterization, and
initial and follow-up scores for the following: Medical
Research Council (MRC) lower extremity muscle strength
(LEMMT), Total Functional Independence Measure
(TFIM), Modified Ashworth Scale (MAS), 10M walk time,
and 2MWT distance. Consistent with Veterans Affairs
(VA) guidelines for veterans on dalfampridine, response to
treatment, compliance, adverse effects, and withdrawals
were assessed at 4, 3, 6, and 12 months following treatment
initiation. All data were prospectively recorded in the
computerized patient record system as part of patient care
by a clinician who was unaware of the study hypothesis.
Table 1 Demographic variables of 20 MS patients on dalfampridine
[mean ± SD (range) or n (%) where applicable]
Grouping variables Sample
Age (years) 55.3 ± 10.8
Sex (M:F) 20:0
Ethnicity (White/Black) 17:3
Age of MS onset (years) 35.2 ± 11.9 (20–58)
MS duration (years) 23.5 ± 14.5 (5–47)





MMSE 28.0 ± 3.2
Visual (n = 17) 3 (18)
Upper limb muscle strength (n = 19) 4.2 ± 0.9
Lower limb muscle strength (n = 19) 3.9 ± 0.9
Sensory complaints [yes] (n = 17) 9 (53)







LEMMT 3.9 ± 0.9 (2–5)
10-meter walk test (sec), initial (n = 19) 28.4 ± 18.7
2-minute walk test (ft), initial (n = 13) 155.4 ± 94.5
Modified Ashworth Score, initial (n = 15) 0.5 ± 0.7 (0–2)
EDSS score, initial (n = 19) 5.5 ± 1.9 (1.5–7.5)
TFIM score, initial (n = 17) 83.7 ± 13.3 (57–104)




EDSS Expanded Disability Status Scale, F female, LEMMT Lower
Extremity Manual Muscle Test, M male, MMSE Mini-Mental State
Examination, MS multiple sclerosis, TFIM Total Functional Inde-
pendence Measure
a Concurrent treatment with interferon, glatiramer, natalizumab
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2.2 Primary Outcome Measures
The 10M and 2MWT were administered to the MS patients
to assess general walking speed and capacity [21, 22]. The
10M walk test measures walking speed (in seconds) of the
patient over a set distance. The patient was instructed to
walk at usual speed using whatever aid was needed as in
everyday life. This test was selected as it is simple and
quick to administer, inexpensive, and is easily generaliz-
able to community walking [21]. It has been found to be a
reliable, valid, and sensitive measure [23–25]. The limita-
tion of the 10M walk test is that the quality of gait is not
assessed and a ceiling effect is apparent at normal walking
speed (1.2–1.4 m/s) [26].
The 2MWT, commonly used to measure walking
capacity or endurance in persons with cardiac and pul-
monary disease, assessed endurance in these patients. The
patient was instructed to cover as much ground as possible
in 2 min walking at a comfortable speed using ambulation
aids as used in their everyday life. Rest periods were
allowed during the evaluation. The distance (in feet) cov-
ered was measured using a Trumeter Mini-Measure Dis-
tance-Measuring Wheel, a device that accurately measures
up to 10,000 feet. The 2-minute timed walk test is a valid,
reliable, and sensitive measure that is easy to administer
[22, 27]. The limiting factors for the 2-minute timed walk
test are pain, mood, and cardiovascular fitness, which can
influence the result [28].
The MAS was administered to measure spasticity [29].
It is widely used, easy to administer, and has good validity
but limited reliability [30–32]. Research has shown that
disability tends to be more related to weakness than spas-
ticity [33]. Therefore, the association between ambulatory
gains and spasticity changes were examined.
MRC scale graded the lower extremity muscle strength
(LEMMT). It is a widely used ordinal measure of power,
with 0 = no movement to 5 = normal movement. It has
established validity and reliability [34]. The major limita-
tion of MRC grading is that the scale neither considers the
range of motion (ROM) for which a movement can be
performed nor defines the strength of resistance against
which a movement can be performed [35].
The TFIM assessed MS-related disability. The TFIM is
a reliable [36] and valid [37] functional assessment
instrument that is widely used in many rehabilitation set-
tings [38] to measure the degree of disability [39]. The
TFIM has 18 items; each item is scored on an ordinal scale
ranging from 1 (‘total assist’: patient performs \25 % of
task) to 7 (‘complete independence’). The resulting score
indicates the level of assistance needed to achieve inde-
pendence and ranges from 18 (totally dependent) to 126
(independent). Thus, increased disability is reflected in
lower TFIM scores.
2.3 Statistical Analysis
All data analyses for this paper were generated using SAS
software, Version 9.2 of the SAS System for Windows
(SAS Institute Inc., Cary, NC, USA). The significance level
for all statistical tests was set a priori at p \ 0.05. Paired
t tests were used to compare the pre-treatment and
12-month follow-up assessments of spasticity, walking
speed, walking capacity, and TFIM. Improvement of
[20 % in walking speed was used to detect clinically
meaningful change. Pearson correlation coefficients were
examined to describe the relationship between 10M and
2MWT at initial evaluation and 12-month follow-up, as
well as between changes in spasticity and ambulation. A
‘responder status’ was defined based on faster walking
speed for three of the four visits during the treatment period
[19]. The difference in the proportion of responders
between the continuation and discontinuation group was
analyzed using the Chi-square test.
Secondary analyses were conducted comparing initial
and 12-month follow-up scores on the 10M, 2MWT, and
MAS according to MS type (relapsing-remitting, RR;
secondary-progressive, SP; or primary-progressive, PP),
MS severity (mild: Expanded Disability Status Scale
[EDSS] score B4.0, or moderate-to-severe: EDSS C4.5),
and duration of dalfampridine use (discontinued after a
minimum of 4 weeks or continued 12-months use) using
repeated measures of analysis of variance (MS type) and
paired t tests. These analyses were not included in the
primary analyses because of the low sample sizes after
dividing the sample into groups.
3 Results
The mean age of MS onset was 35.2 years (SD 11.9) and
mean duration of MS condition was 23.5 years (SD 14.5).
The most common type of MS was RR (55 %) followed by
SP (30 %) and PP (15 %) types. The initial mean MAS,
10M, 2MWT, and LEMMT test scores across the entire
sample were 0.5 ± 0.7, 28.4 ± 18.7 s, 155.4 ± 94.5 feet,
and 3.9 ± 0.9 (2–5), respectively. The mean initial EDSS
and TFIM scale scores were 5.5 ± 1.9, and 83.7 ± 13.3,
respectively. Thus, patients with MS were moderately
functionally impaired with little muscle tone (spasticity).
Table 2 presents the change in the 10M and 2MWT, and
MAS, LEMMT, and TFIM scores. Data were missing for
several patients; therefore, values are only presented for
those with data at both timepoints. Significant improve-
ment was observed for walking speed (p = 0.008), and
walking distance (p = 0.03), but not for spasticity
(p = 0.10) and lower extremity muscle strength (p = 1.0).
The change in 10M represented a 33 % improvement in
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walking speed, exceeding the minimally important clinical
difference of 20 %, and endurance improved by 31 %.
While the MAS score doubled, the score still fell in the
range representing no change in muscle tone. Likewise,
there was no change in the LEMMT score. The correlations
between MAS change and change in walking speed and
endurance did not achieve significance (p [ 0.05). This
improvement in ambulatory ability was mirrored by an
improvement in motor function (p = 0.07); however, it did
not achieve statistical significance.
The correlation between walking speed (10M) and
walking distance (2MWT) was examined for scores
obtained on initial evaluation and at 12-month follow-up
(Fig. 1). The correlation at baseline was not significant
r = -0.38, p = 0.22 (n = 12). However, at 12-months,
there was a significant inverse relationship between walk-
ing speed and walking distance, r = -0.88, p \ 0.0001
(n = 13), indicating that the faster walkers were also able
to walk further distances.
The number of patients who met the responder criterion
was 6/12 (50 %) in the continuation group compared with
2/8 (25 %) in the discontinuation group (p = 0.37). There
was no difference in change in leg strength at 12 months
between responders and non-responders (-0.2 ± 1.0 vs.
0.1 ± 1.1; mean ± SD; p = 0.63).
3.1 Secondary Analyses
No significant differences were observed in change at 12
months for 10M, 2MWT, or MAS according to MS type
(see Appendix 1, electronic supplementary material
[ESM]) or MS severity (see Appendix 2, ESM) [all
p [ 0.05]. However, SP and PP MS patients had the fastest
walking speed and had more endurance compared with the
RR MS patients when on dalfampridine. Similarly, mod-
erate to severely disabled MS patients had the fastest
walking speed and had more endurance compared with the
mildly disabled MS patients when on dalfampridine.
Although no significant differences were observed in
change at 12 months for 10M, 2MWT, and MAS scores
according to the duration for which dalfampridine was
taken (p [ 0.5) (see Appendix 3, ESM), it did show that
veterans who took dalfampridine for a minimum of
4 weeks were able to maintain faster walking speed and
endurance at 12 months when compared with those who
continued taking their medication for 12 months.
4 Discussion
Results of this study in MS patients who were on stable
immunomodulatory therapy confirm the beneficial effect of
dalfampridine in the treatment of veterans with MS and
ambulatory dysfunction [16, 19], but also expands upon the
findings of Goodman et al. [19, 20] by demonstrating the
following: (i) improved ambulation persists when dalfam-
pridine is taken over an extended time period (12 months);
(ii) the change in ambulation speed and endurance is both
clinically relevant and significant; (iii) the changes in
ambulation were not influenced by change in muscle tone
(spasticity), or improvement in muscle strength in the legs;
and (iv) this improvement in ambulation was associated
with an improvement in motor function.
In terms of the major outcome measures of walking
speed and endurance, walking speed improved by 33 %
with a simultaneous increase in endurance (the distance
ambulated) by 31 % for the whole group. Studies by
Goodman et al. [19, 20] showed the average change from
baseline in walking speed in the fampridine-treated group
was 25 %, which is similar to our study results, and this
change was maintained during the 12-month treatment
period. This improvement in walking speed translated into
improved endurance, resulting in them becoming commu-
nity ambulators [40, 41]. The improvements in walking
speed exceed C20 %, which is considered to represent
clinically relevant change [42–44].
While the small sample sizes limit the power and gen-
eralizability of the analyses, the current study also dem-
onstrated that, of the MS types, PP and SP made the most
gains in ambulation compared with the RR group. This was
not unusual given that the PP and SP groups were slow in
ambulation to begin with and ambulated shorter distances
Table 2 Initial and follow-up 10-meter, 2-minute timed walk test and Modified Ashworth Scale (mean ± SD) on initial evaluation and at
12-month follow-up
Variable Initial 12-months follow-up D % Change p-value
10-meter walk test (n = 13) 32.1 (18.9) 21.5 (11.3) -10.5 (11.9) -32.7 0.008
2-minute walk test (n = 8) 163.8 (97.1) 215.0 (88.8) 51.3 (51.4) 31.3 0.03
Modified Ashworth Scale (n = 10) 0.4 (0.8) 0.8 (0.9) 0.4 (0.7) 100 0.10
LEMMT (n = 17) 3.9 (0.9) 3.9 (1.1) 0 (1.1) 0 1.0
TFIM score (n = 14) 84.7 (13.2) 102.2 (13.6) 17.5 (19.3) 20.7 0.07
LEMMT Lower Extremity Manual Muscle Test, TFIM Total Functional Independence Measure
Bold value indicates statistical significant differences
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(more impaired). Similar changes were observed for the
more impaired patients (moderate to severe impairment)
when compared with mildly impaired patients. Both sets of
patients who continued taking the medication and those
who discontinued after a minimum of 4 weeks use were
able to maintain their improved walking speed and
endurance at 12-month follow-up. This improvement in
ambulatory ability translated into improved motor function.
The change in TFIM score was 18 points. A TFIM change
of *20 points is considered a minimally clinically sig-
nificant change [45]. This implied that patients who were
now able to ambulate more were now more able to self-
care and thus less dependent on their caregivers.
The present study also revealed a negative correlation
between walking speed and endurance on initial evaluation
and 12-month follow-up, with slower walking patients also
ambulating shorter distances. However, this association
was statistically significant at 12-month follow-up only.
This finding suggests that the results of the two ambulation
tests are better aligned at the follow-up assessment.
Eight patients (40 %) discontinued dalfampridine use
after 4 weeks. Three patients did so volitionally due to
perceived lack of benefit, while in five patients this was due
to adverse effects which included insomnia in two patients,
and weakness, dizziness, and headache in one patient each.
The limitations of this study include (i) the small sample
size; (ii) the sample comprised of veterans who were all
White men; (iii) it was a single institution study; and (iv)
retrospective analysis with missing data may bias the
findings of this study. However, the strength of this study
lies in the longitudinal follow-up for 12 months with
100 % adherence to intake in 60 % (12/20) of the patient
population studied.
5 Conclusion
Ambulation is crucial for patients with MS. This study
provides evidence that treatment with dalfampridine in
veterans with MS with ambulatory dysfunction produces
clinically meaningful improvement in walking speed and
endurance in the absence of meaningful change in muscle
tone. This improvement in ambulation was associated with
improved motor functioning.
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